| Name | Tlc Care Center |
|---|---|
| Location | 1500 W Warm Springs Rd, Henderson, Nevada |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 255 |
| Occupancy Rate | 68.63% |
| Medicare ID (CCN) | 295071 |
| Legal Business Name | Tlc Holdings, Llc |
| Ownership Type | For Profit - Individual |
| NPI Number | 1154383412 |
| Organization Name | TLC HOLDINGS, LLC |
| Doing Business As | TLC CARE CENTER |
| Address | 1500 W Warm Springs Rd, Henderson, NV 89014 |
| Phone Number | 702-547-6700 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
People who buy their own health insurance are seeing their premiums increases by 15 percent or more in four states, and those in others could be faced with the same, The Associated Press/Seattle Times reports.
Treating a rare type of malignant lung cancer could improve, thanks to near-infrared irradiation and a cancer-targeting compound. Nagoya University oncologist Kazuhide Sato and colleagues tested the treatment and published their findings in the journal Cells.
Brainlab, a leader in software-driven medical technology, announced today the first patient procedures with Curve Image Guided Surgery at the University of California San Francisco (UCSF) Medical Center's Neuro-Oncology Clinic.
› Verified 3 days ago
| NPI Number | 1841927126 |
| Organization Name | TLC SNF OPERATIONS LLC |
| Address | 1500 W Warm Springs Rd, Henderson, NV 89014 |
| Phone Number | 702-547-6700 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
People who buy their own health insurance are seeing their premiums increases by 15 percent or more in four states, and those in others could be faced with the same, The Associated Press/Seattle Times reports.
Treating a rare type of malignant lung cancer could improve, thanks to near-infrared irradiation and a cancer-targeting compound. Nagoya University oncologist Kazuhide Sato and colleagues tested the treatment and published their findings in the journal Cells.
Brainlab, a leader in software-driven medical technology, announced today the first patient procedures with Curve Image Guided Surgery at the University of California San Francisco (UCSF) Medical Center's Neuro-Oncology Clinic.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
People who buy their own health insurance are seeing their premiums increases by 15 percent or more in four states, and those in others could be faced with the same, The Associated Press/Seattle Times reports.
Treating a rare type of malignant lung cancer could improve, thanks to near-infrared irradiation and a cancer-targeting compound. Nagoya University oncologist Kazuhide Sato and colleagues tested the treatment and published their findings in the journal Cells.
Brainlab, a leader in software-driven medical technology, announced today the first patient procedures with Curve Image Guided Surgery at the University of California San Francisco (UCSF) Medical Center's Neuro-Oncology Clinic.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.04 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.42 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 57.63 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.94 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.6 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.07 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.65 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.96 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 18.66 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 91.07 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.49 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.01 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 23.05 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.09 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.1 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 76.79 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 88.6 | 82.93 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
People who buy their own health insurance are seeing their premiums increases by 15 percent or more in four states, and those in others could be faced with the same, The Associated Press/Seattle Times reports.
Treating a rare type of malignant lung cancer could improve, thanks to near-infrared irradiation and a cancer-targeting compound. Nagoya University oncologist Kazuhide Sato and colleagues tested the treatment and published their findings in the journal Cells.
Brainlab, a leader in software-driven medical technology, announced today the first patient procedures with Curve Image Guided Surgery at the University of California San Francisco (UCSF) Medical Center's Neuro-Oncology Clinic.
› Verified 3 days ago
Lake Mead Health And Rehabilitation Center Location: 1180 E. Lake Mead Drive, Henderson, Nevada 89015 Phone: (702) 565-8555 | |
Delmar Gardens Of Green Valley Location: 100 Delmar Gardens Drive, Henderson, Nevada 89074 Phone: (702) 361-6111 | |
Horizon Ridge Skilled Nursing & Rehabilitation Ctr Location: 2855 W. Horizon Ridge Parkway, Henderson, Nevada 89052 Phone: (714) 241-5600 |